The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert ...

CCCTN registry data reinforce the message that DanGer Shock’s findings supporting MCS apply narrowly to patients studied.

The following is a summary of “Role of Inflammation in Early Left Ventricular Thrombus Formation Following ST-Elevation Myocardial Infarction—A Matched Case-Control Study,” published in the October ...

The Society for Cardiovascular Angiography & Interventions (SCAI) is pleased to announce the publication of the Expert Consensus Statement on the Management of Patients with STEMI Referred for Primary ...

The experts provide a how-to on dealing with sticky situations, such as no-flow and large thrombus, during PCI for STEMI.

A study of over 450,000 NSTEMI admissions reveals that diabetics face disparities in care, with less invasive treatment ...

The following is a summary of "Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results," published in the October 2024 issue of Cardiology by Stone et al. In the ...

"By providing these consensus key points, we are not only helping to ensure consistency in treatment approaches but also aiming to improve the overall quality of care for STEMI patients globally.

For patients with either NSTEMI or STEMI, American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend that intravenous unfractionated heparin (UFH) be dosed by weight ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug ...